Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Madrigal Pharmaceuticals, Inc. (MDGL) since 2015 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Madrigal Pharmaceuticals, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1157601.
Total stock buying since 2015: $183,011,348.
Total stock sales since 2015: $713,415,925.
Total stock option exercises since 2015: $28,231,820.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 234,301 | $86,805,565 | 375,936 | $134,215,803 | 407,873 | $7,855,850 |
| 2024 | 0 | $0 | 299,930 | $74,745,732 | 288,931 | $11,112,686 |
| 2023 | 458,873 | $82,756,521 | 63,089 | $16,791,541 | 63,089 | $5,817,424 |
| 2022 | 0 | $0 | 37,000 | $10,185,215 | 37,000 | $2,450,330 |
| 2020 | 0 | $0 | 60,000 | $6,584,388 | 0 | $0 |
| 2019 | 0 | $0 | 2,400,000 | $253,128,000 | 0 | $0 |
| 2018 | 10,000 | $1,216,014 | 747,151 | $209,719,024 | 37,957 | $995,530 |
| 2017 | 9,100 | $145,748 | 0 | $0 | 0 | $0 |
| 2015 | 6,907,143 | $12,087,500 | 17,014,412 | $8,046,222 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-08 | 234,301 | $86,805,565 | 241,363 | $87,620,191 | 232,443 | $2,266,684 |
| 2025-07 | 0 | $0 | 60,377 | $21,323,105 | 60,377 | $570,559 |
| 2025-03 | 0 | $0 | 33,636 | $11,216,970 | 29,583 | $2,419,179 |
| 2025-02 | 0 | $0 | 35,470 | $12,498,055 | 85,470 | $2,599,428 |
| 2025-01 | 0 | $0 | 5,090 | $1,557,482 | 0 | $0 |
| 2024-12 | 0 | $0 | 3,600 | $1,136,008 | 0 | $0 |
| 2024-11 | 0 | $0 | 10,000 | $3,259,820 | 10,000 | $73,600 |
| 2024-09 | 0 | $0 | 6,363 | $1,551,490 | 0 | $0 |
| 2024-06 | 0 | $0 | 3,900 | $1,102,000 | 3,900 | $341,311 |
| 2024-05 | 0 | $0 | 23,525 | $5,083,888 | 22,489 | $2,311,082 |
| 2024-04 | 0 | $0 | 252,542 | $62,612,526 | 252,542 | $8,386,693 |
| 2023-12 | 136,370 | $30,012,306 | 10,600 | $2,409,229 | 10,600 | $917,622 |
| 2023-11 | 322,503 | $52,744,215 | 7,000 | $1,409,431 | 7,000 | $516,250 |
| 2023-03 | 0 | $0 | 5,000 | $1,374,665 | 5,000 | $439,600 |
| 2023-02 | 0 | $0 | 5,000 | $1,358,325 | 5,000 | $439,600 |
| 2023-01 | 0 | $0 | 35,489 | $10,239,891 | 35,489 | $3,504,352 |
| 2022-12 | 0 | $0 | 37,000 | $10,185,215 | 37,000 | $2,450,330 |
| 2020-08 | 0 | $0 | 60,000 | $6,584,388 | 0 | $0 |
| 2019-12 | 0 | $0 | 2,400,000 | $253,128,000 | 0 | $0 |
| 2018-11 | 10,000 | $1,216,014 | 30,000 | $3,566,800 | 10,000 | $164,600 |
| 2018-09 | 0 | $0 | 0 | $0 | 20,000 | $189,000 |
| 2018-06 | 0 | $0 | 717,151 | $206,152,224 | 7,957 | $641,930 |
| 2017-08 | 9,100 | $145,748 | 0 | $0 | 0 | $0 |
| 2015-12 | 0 | $0 | 4,299,991 | $1,671,746 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-08-21 | Sibold William John (President and CEO) | Sale | 7,616 | 400.52 | 3,050,345 |
| 2025-08-20 | Baker Brothers Life Sciences Lp | Buy | 59,901 | 384.95 | 23,059,129 |
| 2025-08-18 | Kelley Shannon T (General Counsel) | Sale | 1,304 | 371.08 | 483,892 |
| 2025-08-18 | Baker Brothers Life Sciences Lp | Buy | 105,782 | 368.48 | 38,816,419 |
| 2025-08-15 | Bate Kenneth (Director) | Sale | 10,000 | 365.88 | 3,658,830 |
| 2025-08-15 | Bate Kenneth (Director) | Option Ex | 10,000 | 16.46 | 164,600 |
| 2025-08-13 | Friedman Paul A (Director) | Sale | 129,172 | 366.29 | 47,314,411 |
| 2025-08-13 | Friedman Paul A (Director) | Option Ex | 129,172 | 9.45 | 1,220,675 |
| 2025-08-12 | Taub Rebecca (Director) | Sale | 43,263 | 355.31 | 15,371,992 |
| 2025-08-12 | Taub Rebecca (Director) | Option Ex | 43,263 | 9.45 | 408,835 |
| 2025-08-12 | Friedman Paul A (Director) | Sale | 43,605 | 355.37 | 15,495,778 |
| 2025-08-12 | Friedman Paul A (Director) | Option Ex | 43,605 | 9.45 | 412,067 |
| 2025-08-11 | Taub Rebecca (Director) | Sale | 3,200 | 350.60 | 1,121,920 |
| 2025-08-11 | Taub Rebecca (Director) | Option Ex | 3,200 | 9.45 | 30,239 |
| 2025-08-11 | Friedman Paul A (Director) | Sale | 3,203 | 350.62 | 1,123,023 |
| 2025-08-11 | Friedman Paul A (Director) | Option Ex | 3,203 | 9.45 | 30,268 |
| 2025-07-18 | Taub Rebecca (Director) | Sale | 1,000 | 350.00 | 350,005 |
| 2025-07-18 | Taub Rebecca (Director) | Option Ex | 1,000 | 9.45 | 9,450 |
| 2025-07-18 | Friedman Paul A (Director) | Sale | 1,400 | 350.03 | 490,043 |
| 2025-07-18 | Friedman Paul A (Director) | Option Ex | 1,400 | 9.45 | 13,229 |
| 2025-07-17 | Taub Rebecca (Director) | Sale | 2,657 | 350.79 | 932,059 |
| 2025-07-17 | Taub Rebecca (Director) | Option Ex | 2,657 | 9.45 | 25,108 |
| 2025-07-17 | Friedman Paul A (Director) | Sale | 2,700 | 350.83 | 947,254 |
| 2025-07-17 | Friedman Paul A (Director) | Option Ex | 2,700 | 9.45 | 25,514 |
| 2025-07-16 | Taub Rebecca (Director) | Sale | 26,444 | 353.54 | 9,348,958 |
| 2025-07-16 | Taub Rebecca (Director) | Option Ex | 26,444 | 9.45 | 249,895 |
| 2025-07-16 | Friedman Paul A (Director) | Sale | 26,176 | 353.56 | 9,254,786 |
| 2025-07-16 | Friedman Paul A (Director) | Option Ex | 26,176 | 9.45 | 247,363 |
| 2025-03-13 | Craves Fred B (Director) | Sale | 7,742 | 326.58 | 2,528,366 |
| 2025-03-13 | Craves Fred B (Director) | Option Ex | 7,742 | 65.06 | 503,694 |
| 2025-03-12 | Craves Fred B (Director) | Sale | 7,728 | 332.58 | 2,570,178 |
| 2025-03-12 | Craves Fred B (Director) | Option Ex | 7,728 | 88.06 | 680,527 |
| 2025-03-10 | Dier Mardi (SVP and CFO) | Sale | 258 | 323.04 | 83,344 |
| 2025-03-05 | Waltermire Robert E. (Senior VP, Chief Pharma Dev.) | Sale | 14,113 | 340.42 | 4,804,361 |
| 2025-03-05 | Waltermire Robert E. (Senior VP, Chief Pharma Dev.) | Option Ex | 14,113 | 87.50 | 1,234,958 |
| 2025-03-03 | Huntsman Carole (Chief Commercial Officer) | Sale | 1,834 | 323.86 | 593,959 |
| 2025-03-03 | Dier Mardi (SVP and CFO) | Sale | 1,961 | 324.71 | 636,762 |
| 2025-02-27 | Daly James M (Director) | Sale | 15,470 | 347.75 | 5,379,615 |
| 2025-02-27 | Daly James M (Director) | Option Ex | 15,470 | 88.06 | 1,362,288 |
| 2025-02-27 | Sibold William John (President and CEO) | Option Ex | 50,000 | .00 | 0 |
| 2025-02-27 | Bate Kenneth (Director) | Sale | 20,000 | 355.92 | 7,118,440 |
| 2025-02-27 | Bate Kenneth (Director) | Option Ex | 20,000 | 61.86 | 1,237,140 |
| 2025-01-24 | Huntsman Carole (Chief Commercial Officer) | Sale | 347 | 335.24 | 116,328 |
| 2025-01-24 | Waltermire Robert E. (Senior VP, Chief Pharma Dev.) | Sale | 103 | 335.24 | 34,529 |
| 2025-01-24 | Sibold William John (President and CEO) | Sale | 1,584 | 335.24 | 531,020 |
| 2025-01-24 | Taub Rebecca (Pres., R&D, and CMO) | Sale | 648 | 335.24 | 217,235 |
| 2025-01-17 | Kelley Shannon T (General Counsel) | Sale | 277 | 273.41 | 75,734 |
| 2025-01-17 | Waltermire Robert E. (Senior VP, Chief Pharma Dev.) | Sale | 442 | 273.41 | 120,847 |
| 2025-01-17 | Taub Rebecca (Pres., R&D, and CMO) | Sale | 1,689 | 273.41 | 461,789 |
| 2024-12-03 | Craves Fred B (Director) | Sale | 3,600 | 315.56 | 1,136,008 |
| 2024-11-07 | Levy Richard S | Sale | 5,000 | 350.00 | 1,750,000 |
| 2024-11-07 | Levy Richard S | Option Ex | 5,000 | 7.36 | 36,800 |
| 2024-11-01 | Levy Richard S | Sale | 5,000 | 301.96 | 1,509,820 |
| 2024-11-01 | Levy Richard S | Option Ex | 5,000 | 7.36 | 36,800 |
| 2024-09-09 | Sibold William John (President and CEO) | Sale | 6,363 | 243.83 | 1,551,490 |
| 2024-06-14 | Waltermire Robert E. (Senior VP, Chief Pharma Dev.) | Sale | 1,900 | 280.00 | 532,000 |
| 2024-06-14 | Waltermire Robert E. (Senior VP, Chief Pharma Dev.) | Option Ex | 1,900 | 87.09 | 165,471 |
| 2024-06-12 | Waltermire Robert E. (Senior VP, Chief Pharma Dev.) | Sale | 2,000 | 285.00 | 570,000 |
| 2024-06-12 | Waltermire Robert E. (Senior VP, Chief Pharma Dev.) | Option Ex | 2,000 | 87.92 | 175,840 |
| 2024-05-21 | Waltermire Robert E. (Senior VP, Chief Pharma Dev.) | Sale | 1,036 | 231.34 | 239,668 |
| 2024-05-14 | Craves Fred B | Sale | 22,489 | 215.40 | 4,844,220 |
| 2024-05-14 | Craves Fred B | Option Ex | 22,489 | 102.77 | 2,311,082 |
| 2024-04-08 | Taub Rebecca (Pres., R&D, and CMO) | Sale | 2,676 | 246.17 | 658,758 |
| 2024-04-08 | Taub Rebecca (Pres., R&D, and CMO) | Option Ex | 2,676 | 9.45 | 25,288 |
| 2024-04-08 | Friedman Paul A | Sale | 26,270 | 245.85 | 6,458,505 |
| 2024-04-08 | Friedman Paul A | Option Ex | 26,270 | 9.45 | 248,251 |
| 2024-04-05 | Taub Rebecca (Pres., R&D, and CMO) | Sale | 27,506 | 242.86 | 6,680,162 |
| 2024-04-05 | Taub Rebecca (Pres., R&D, and CMO) | Option Ex | 27,506 | 9.45 | 259,931 |
| 2024-04-05 | Friedman Paul A (Director) | Sale | 27,613 | 243.19 | 6,715,288 |
| 2024-04-05 | Friedman Paul A (Director) | Option Ex | 27,613 | 9.45 | 260,942 |
| 2024-04-04 | Taub Rebecca (Pres., R&D, and CMO) | Sale | 18,537 | 244.50 | 4,532,259 |
| 2024-04-04 | Taub Rebecca (Pres., R&D, and CMO) | Option Ex | 18,537 | 9.45 | 175,174 |
| 2024-04-04 | Friedman Paul A (Director) | Sale | 18,710 | 244.68 | 4,578,018 |
| 2024-04-04 | Friedman Paul A (Director) | Option Ex | 18,710 | 9.45 | 176,809 |
| 2024-04-03 | Taub Rebecca (Pres., R&D, and CMO) | Sale | 27,845 | 244.41 | 6,805,457 |
| 2024-04-03 | Taub Rebecca (Pres., R&D, and CMO) | Option Ex | 27,845 | 9.45 | 263,135 |
| 2024-04-03 | Friedman Paul A (Director) | Sale | 27,407 | 244.38 | 6,697,585 |
| 2024-04-03 | Friedman Paul A (Director) | Option Ex | 27,407 | 9.45 | 258,996 |
| 2024-04-02 | Daly James M (Director) | Sale | 10,912 | 245.69 | 2,680,936 |
| 2024-04-02 | Daly James M (Director) | Option Ex | 10,912 | 105.08 | 1,146,632 |
| 2024-04-02 | Bate Kenneth (Director) | Sale | 11,212 | 246.16 | 2,759,979 |
| 2024-04-02 | Bate Kenneth (Director) | Option Ex | 11,212 | 105.08 | 1,178,156 |
| 2024-04-01 | Daly James M (Director) | Sale | 21,577 | 260.94 | 5,630,367 |
| 2024-04-01 | Daly James M (Director) | Option Ex | 21,577 | 102.77 | 2,217,360 |
| 2024-04-01 | Levy Richard S | Sale | 11,000 | 260.36 | 2,863,916 |
| 2024-04-01 | Levy Richard S | Option Ex | 11,000 | 59.21 | 651,310 |
| 2024-04-01 | Bate Kenneth (Director) | Sale | 21,277 | 260.91 | 5,551,296 |
| 2024-04-01 | Bate Kenneth (Director) | Option Ex | 21,277 | 71.66 | 1,524,709 |
| 2023-12-15 | Waltermire Robert E. (Senior VP, Chief Pharma Dev.) | Sale | 2,000 | 238.50 | 477,000 |
| 2023-12-15 | Waltermire Robert E. (Senior VP, Chief Pharma Dev.) | Option Ex | 2,000 | 87.92 | 175,840 |
| 2023-12-14 | Waltermire Robert E. (Senior VP, Chief Pharma Dev.) | Sale | 2,000 | 232.50 | 465,000 |
| 2023-12-14 | Waltermire Robert E. (Senior VP, Chief Pharma Dev.) | Option Ex | 2,000 | 87.92 | 175,840 |
| 2023-12-14 | Baker Brothers Life Sciences Lp (Director) | Buy | 20,633 | 228.37 | 4,711,978 |
| 2023-12-13 | Waltermire Robert E. (Senior VP, Chief Pharma Dev.) | Sale | 2,500 | 225.50 | 563,750 |
| 2023-12-13 | Waltermire Robert E. (Senior VP, Chief Pharma Dev.) | Option Ex | 2,500 | 87.92 | 219,800 |
| 2023-12-13 | Baker Brothers Life Sciences Lp (Director) | Buy | 81,159 | 220.73 | 17,914,226 |
| 2023-12-12 | Waltermire Robert E. (Senior VP, Chief Pharma Dev.) | Sale | 1,300 | 217.50 | 282,750 |
| 2023-12-12 | Waltermire Robert E. (Senior VP, Chief Pharma Dev.) | Option Ex | 1,300 | 87.92 | 114,296 |
| 2023-12-12 | Baker Brothers Life Sciences Lp (Director) | Buy | 34,578 | 213.61 | 7,386,102 |
| 2023-12-05 | Lynch Brian Joseph (SVP and General Counsel) | Sale | 1,000 | 227.33 | 227,330 |
| 2023-12-05 | Lynch Brian Joseph (SVP and General Counsel) | Option Ex | 1,000 | 87.09 | 87,090 |
| 2023-12-04 | Lynch Brian Joseph (SVP and General Counsel) | Sale | 1,800 | 218.56 | 393,399 |
| 2023-12-04 | Lynch Brian Joseph (SVP and General Counsel) | Option Ex | 1,800 | 80.42 | 144,756 |
| 2023-11-30 | Lynch Brian Joseph (SVP and General Counsel) | Sale | 3,000 | 204.58 | 613,731 |
| 2023-11-30 | Lynch Brian Joseph (SVP and General Counsel) | Option Ex | 3,000 | 73.75 | 221,250 |
| 2023-11-29 | Lynch Brian Joseph (SVP and General Counsel) | Sale | 4,000 | 198.93 | 795,700 |
| 2023-11-29 | Lynch Brian Joseph (SVP and General Counsel) | Option Ex | 4,000 | 73.75 | 295,000 |
| 2023-11-21 | Baker Brothers Life Sciences Lp (Director) | Buy | 64,350 | 187.22 | 12,047,349 |
| 2023-11-20 | Baker Brothers Life Sciences Lp (Director) | Buy | 20,709 | 186.18 | 3,855,580 |
| 2023-11-17 | Baker Brothers Life Sciences Lp (Director) | Buy | 46,370 | 172.91 | 8,018,068 |
| 2023-11-15 | Baker Brothers Life Sciences Lp (Director) | Buy | 15,199 | 161.97 | 2,461,721 |
| 2023-11-14 | Baker Brothers Life Sciences Lp (Director) | Buy | 71,848 | 154.99 | 11,130,478 |
| 2023-11-13 | Baker Brothers Life Sciences Lp (Director) | Buy | 69,839 | 141.51 | 9,883,196 |
| 2023-03-01 | Waltermire Robert E. (Senior VP, Chief Pharma Dev.) | Sale | 5,000 | 274.93 | 1,374,665 |
| 2023-03-01 | Waltermire Robert E. (Senior VP, Chief Pharma Dev.) | Option Ex | 5,000 | 87.92 | 439,600 |
| 2023-02-28 | Waltermire Robert E. (Senior VP, Chief Pharma Dev.) | Sale | 5,000 | 271.67 | 1,358,325 |
| 2023-02-28 | Waltermire Robert E. (Senior VP, Chief Pharma Dev.) | Option Ex | 5,000 | 87.92 | 439,600 |
| 2023-01-17 | Levy Richard S (Director) | Sale | 22,489 | 291.63 | 6,558,512 |
| 2023-01-17 | Levy Richard S (Director) | Option Ex | 22,489 | 102.77 | 2,311,082 |
| 2023-01-03 | Lynch Brian Joseph (SVP and General Counsel) | Sale | 13,000 | 283.18 | 3,681,379 |
| 2023-01-03 | Lynch Brian Joseph (SVP and General Counsel) | Option Ex | 13,000 | 91.79 | 1,193,270 |
| 2022-12-23 | Sukhija Remy (Chief Commercial Officer) | Sale | 30,000 | 275.27 | 8,258,220 |
| 2022-12-23 | Sukhija Remy (Chief Commercial Officer) | Option Ex | 30,000 | 60.26 | 1,807,800 |
| 2022-12-23 | Lynch Brian Joseph (SVP and General Counsel) | Sale | 7,000 | 275.29 | 1,926,995 |
| 2022-12-23 | Lynch Brian Joseph (SVP and General Counsel) | Option Ex | 7,000 | 91.79 | 642,530 |
| 2020-08-19 | Bay City Capital Fund Iv Co Invesment Fund Lp (10% Owner) | Sale | 7,303 | 107.64 | 786,094 |
| 2020-08-19 | Craves Fred B (Director) | Sale | 7,303 | 107.64 | 786,094 |
| 2020-08-18 | Bay City Capital Fund Iv Co Invesment Fund Lp (10% Owner) | Sale | 10,197 | 110.03 | 1,121,975 |
| 2020-08-18 | Craves Fred B (Director) | Sale | 10,197 | 110.03 | 1,121,975 |
| 2020-08-17 | Bay City Capital Fund Iv Co Invesment Fund Lp (10% Owner) | Sale | 12,500 | 110.73 | 1,384,125 |
| 2020-08-17 | Craves Fred B (Director) | Sale | 12,500 | 110.73 | 1,384,125 |
| 2019-12-13 | Bay City Capital Fund Iv Co Invesment Fund Lp (10% Owner) | Sale | 1,200,000 | 105.47 | 126,564,000 |
| 2019-12-13 | Craves Fred B (Director) | Sale | 1,200,000 | 105.47 | 126,564,000 |
| 2018-11-21 | Milligan David V (Director) | Sale | 20,000 | 112.54 | 2,250,800 |
| 2018-11-20 | Friedman Paul A (Chief Executive Officer) | Buy | 4,000 | 117.88 | 471,520 |
| 2018-11-19 | Friedman Paul A (Chief Executive Officer) | Buy | 4,000 | 124.00 | 496,000 |
| 2018-11-19 | Milligan David V (Director) | Sale | 10,000 | 131.60 | 1,316,000 |
| 2018-11-19 | Craves Fred B | Buy | 2,000 | 124.25 | 248,494 |
| 2018-11-14 | Milligan David V | Option Ex | 10,000 | 16.46 | 164,600 |
| 2018-09-18 | Milligan David V | Option Ex | 20,000 | 9.45 | 189,000 |
| 2018-06-11 | Taub Rebecca (Chief Medical Officer, EVP R&D) | Sale | 73,526 | 287.46 | 21,135,783 |
| 2018-06-11 | Schneebaum Marc R (Chief Financial Officer) | Sale | 10,099 | 287.46 | 2,903,058 |
| 2018-06-11 | Schneebaum Marc R (Chief Financial Officer) | Option Ex | 7,957 | 80.67 | 641,930 |
| 2018-06-11 | Bay City Capital Llc | Sale | 280,000 | 287.46 | 80,488,800 |
| 2018-06-11 | Friedman Paul A (Chief Executive Officer) | Sale | 73,526 | 287.46 | 21,135,783 |
| 2018-06-11 | Craves Fred B | Sale | 280,000 | 287.46 | 80,488,800 |
| 2017-08-23 | Levy Richard S | Buy | 2,000 | 16.14 | 32,280 |
| 2017-08-22 | Levy Richard S | Buy | 3,550 | 16.09 | 57,112 |
| 2017-08-21 | Levy Richard S | Buy | 3,550 | 15.88 | 56,356 |
| 2015-12-14 | Gollust Keith R | Sale | 300,000 | .32 | 96,600 |
| 2015-12-11 | Gollust Keith R | Sale | 300,000 | .37 | 111,000 |
| 2015-12-09 | Gollust Keith R | Sale | 145,892 | .38 | 55,293 |
| 2015-12-08 | Kovner Bruce | Sale | 1,369,639 | .37 | 506,766 |
| 2015-12-08 | Gollust Keith R | Sale | 300,000 | .38 | 114,000 |
| 2015-12-07 | Kovner Bruce | Sale | 100 | .41 | 41 |
| 2015-12-07 | Gollust Keith R | Sale | 300,000 | .39 | 115,800 |
| 2015-12-04 | Kovner Bruce | Sale | 153,607 | .41 | 63,286 |
| 2015-12-03 | Kovner Bruce | Sale | 262,434 | .41 | 108,647 |
| 2015-12-02 | Kovner Bruce | Sale | 687,603 | .43 | 293,606 |
| 2015-12-01 | Kovner Bruce | Sale | 480,716 | .43 | 206,707 |
| 2015-11-30 | Kovner Bruce | Sale | 640,505 | .43 | 277,979 |
| 2015-11-27 | Kovner Bruce | Sale | 934,595 | .49 | 462,624 |
| 2015-11-25 | Kovner Bruce | Sale | 1,503,720 | .49 | 733,815 |
| 2015-11-24 | Kovner Bruce | Sale | 538,129 | .44 | 237,314 |
| 2015-11-23 | Kovner Bruce | Sale | 635,453 | .44 | 277,692 |
| 2015-11-20 | Kovner Bruce | Sale | 230,283 | .44 | 102,015 |
| 2015-11-19 | Kovner Bruce | Sale | 1,174,651 | .48 | 559,133 |
| 2015-11-18 | Kovner Bruce | Sale | 108,154 | .43 | 46,830 |
| 2015-11-17 | Kovner Bruce | Sale | 700,618 | .42 | 295,660 |
| 2015-11-17 | Gollust Keith R | Sale | 100,000 | .41 | 41,400 |
| 2015-11-16 | Kovner Bruce | Sale | 15,530 | .43 | 6,755 |
| 2015-11-13 | Kovner Bruce | Sale | 507,788 | .43 | 219,364 |
| 2015-11-12 | Kovner Bruce | Sale | 733,564 | .47 | 347,709 |
| 2015-11-11 | Kovner Bruce | Sale | 1,080,941 | .50 | 538,308 |
| 2015-11-10 | Kovner Bruce | Sale | 1,397,114 | .55 | 769,809 |
| 2015-11-10 | Gollust Keith R | Sale | 188,322 | .55 | 103,012 |
| 2015-11-09 | Kovner Bruce | Sale | 2,225,054 | .61 | 1,355,057 |
| 2015-04-06 | Kovner Bruce | Buy | 6,857,143 | 1.75 | 12,000,000 |
| 2015-04-06 | Wilson Robert N | Buy | 50,000 | 1.75 | 87,500 |
Insider trading activities including stock purchases, stock sales, and option exercises of MDGL listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Madrigal Pharmaceuticals, Inc. (symbol MDGL, CIK number 1157601) see the Securities and Exchange Commission (SEC) website.